Måndag 8 December | 07:30:55 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-04 08:00 Kvartalsrapport 2026-Q3
2026-08-19 08:00 Kvartalsrapport 2026-Q2
2026-05-21 N/A Årsstämma
2026-05-13 08:00 Kvartalsrapport 2026-Q1
2026-02-18 08:00 Bokslutskommuniké 2025
2025-11-20 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2025-05-22 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-26 08:00:00

Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive GERD, as well as the potential of Cinclus Pharma’s drug candidate linaprazan glurate. The event will take place on Thursday, 11 December, 15:00–16:00 CET / 09:00–10:00 AM EST.

Following the presentation, there will be an opportunity to ask questions. A recorded version of the webcast will be available on the company’s website after the event.

For registration and further information about the event, please follow the link below:
 
Cinclus Pharma Virtual KOL Event - LifeSci Events

About Professor Prateek Sharma
Prateek Sharma, MD, MASGE, FACP, FACG is Professor of Medicine and the Elaine Blaylock Endowed Professor at the Cancer Center in Kansas City, USA. Dr. Sharma has been at the forefront in improving diagnosis and management of GI diseases and cancer, specifically esophageal diseases, GERD, Barrett’s esophagus, imaging, artificial intelligence, digital health, sustainable healthcare and endoscopic treatments. He is a world-renowned physician, teacher, and educator. He has over 550 publications, including guidelines and book chapters, and is regularly invited to present at major national and international meetings. He has published several important textbooks in medicine. Dr. Sharma continues to publish in several high-profile international journals, including the New England Journal of Medicine, JAMA, Annals of Internal Medicine, Gastroenterology, American Journal of Gastroenterology and Gastrointestinal Endoscopy.